Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia


Chronic Lymphocytic Leukemia

Trial Phase

Phase 2

Trial Purpose and Description

Trial Purpose

This study will determine whether or not Lenalidomide improves effectiveness of treatment for chronic lymphocytic leukemia following chemotherapy with two drugs commonly used to treat the disease (bendamustine and rituximab).

Participation Guidelines

18 Years - 90 Years

Eligibility Criteria

Inclusion Criteria:

- Previous induction treatment with bendamustine and rituximab

- 18 or more years of age

- chronic lymphocytic leukemia

- ECOG performance status less than or equal to 2

- Absolute neutrophile count more than 1,000

- Platelet count more than 70,000

Exclusion Criteria:

- Serious medical condition that would prevent treatment with lenalidomide

- Evidence of tumor lysis syndrome

- Any prior treatment with lenalidomide
Celgene Corporation
Yale University
March 2012
Last Updated:
October 22, 2014
Study HIC#:

Clinicaltrials.gov ID: NCT01465230